HMGCR gene polymorphism is associated with stroke risk in the EPIC-Norfolk study

Background Earlier, a G/T single nucleotide polymorphism (SNP) in the HMGCR gene was shown to significantly reduce the overall serum lipids response to pravastatin. This study aimed to investigate the relationship of the rs17238540 SNP with coronary heart disease, stroke and cardiovascular disease risk. Design Cross-sectional study from the European Prospective Investigation into Cancer and Nutrition-Norfolk cohort. Methods Genotype was determined by pyrosequencing 23 011 participants, for whom clinical and biochemical data were available. Baseline risk factors according to genotype were evaluated, and the risk for fatal and nonfatal stroke, ischaemic heart disease and all types of cardiovascular diseases were assessed by logistic regression after approximately 11 years of follow-up. Results The G allele carriers presented 1.4 mmHg higher systolic blood pressure and 0.8 mmHg higher diastolic blood pressure than those who were TT carriers. They also presented higher risk of prevalent total (odds ratio: 1.44, 95% confidence interval: 1.05-1.97, P = 0.025) and nonfatal (odds ratio: 1.56, 95% confidence interval: 1.12-2.17, P = 0.009) stroke events compared with the TT individuals in the multivariate models. Conclusion An association between the rs17238540 SNP and stroke risk was observed, independent of the effect of the SNP on the blood pressure. The possible mechanisms involved, besides the effect on blood pressure, might be related to pleiotropic functions of the HMGCR, and remain to be explored.

[1]  V. Plaiasu.  Update in genetics. , 2011, Maedica.

[2]  J. Bogousslavsky,et al.  Statins and stroke prevention , 2009, Expert review of cardiovascular therapy.

[3]  R. Luben,et al.  A HMGCR polymorphism is associated with relations between blood pressure and urinary sodium and potassium ratio in the Epic-Norfolk Study. , 2009, Journal of the American Society of Hypertension : JASH.

[4]  R. Luben,et al.  Risk factors for first-ever stroke in the EPIC-Norfolk prospective population-based study , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[5]  R. Luben,et al.  Accuracy of death certification and hospital record linkage for identification of incident stroke , 2008, BMC medical research methodology.

[6]  N. Day,et al.  Associations between dietary methods and biomarkers, and between fruits and vegetables and risk of ischaemic heart disease, in the EPIC Norfolk Cohort Study. , 2008, International journal of epidemiology.

[7]  J. Ordovás,et al.  Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. , 2008, Atherosclerosis.

[8]  T. Lumley,et al.  Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke , 2008, Pharmacogenetics and genomics.

[9]  C. Carty,et al.  Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. , 2008, The American journal of cardiology.

[10]  T. Lumley,et al.  Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke , 2008, Pharmacogenetics and genomics.

[11]  T. Lumley,et al.  beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. , 2008, American journal of hypertension.

[12]  R. Luben,et al.  Apolipoprotein E polymorphisms, dietary fat and fibre, and serum lipids: the EPIC Norfolk study. , 2007, European heart journal.

[13]  Joanne M. Meyer,et al.  Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipientss⃞ Published, JLR Papers in Press, June 11, 2007. , 2007, Journal of Lipid Research.

[14]  H. Markus,et al.  Update on genetics of stroke and cerebrovascular disease 2005. , 2005, Stroke.

[15]  P. Touboul,et al.  Stroke prevention, blood cholesterol and statins. , 2005, Acta neurologica Taiwanica.

[16]  E. O’Brien,et al.  Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). , 2004, The American journal of clinical nutrition.

[17]  David Posada,et al.  Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction , 2004 .

[18]  P. Rothwell,et al.  Heritability of Ischemic Stroke in Relation to Age, Vascular Risk Factors, and Subtypes of Incident Stroke in Population-Based Studies , 2004, Stroke.

[19]  X. Kong,et al.  8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease , 2004, Lipids.

[20]  M. Alberts.  Genetics of cerebrovascular disease. , 2004, Stroke.

[21]  P. Rothwell,et al.  Systematic Review of Methods and Results of Studies of the Genetic Epidemiology of Ischemic Stroke , 2003, Stroke.

[22]  Mark Gurney,et al.  The gene encoding phosphodiesterase 4D confers risk of ischemic stroke , 2003, Nature Genetics.

[23]  R. Bordet,et al.  Stroke prevention: Management of modifiable vascular risk factors , 2003, Journal of Neurology.

[24]  W. März,et al.  HMG-CoA Reductase Inhibition: Anti-Inflammatory Effects beyond Lipid Lowering? , 2003, Journal of cardiovascular risk.

[25]  Geoffrey Cloud,et al.  Evaluating the Genetic Component of Ischemic Stroke Subtypes: A Family History Study , 2003, Stroke.

[26]  Jo Mitchell,et al.  Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study , 2003, Public Health Nutrition.

[27]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[28]  Majid Ezzati,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[29]  R. Mensink,et al.  Relationship of genetic variation in genes encoding apolipoprotein A‐IV, scavenger receptor BI, HMG‐CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption , 2002, European journal of clinical investigation.

[30]  M. Lechleitner.  Non Lipid Related Effects of Statins , 2002 .

[31]  G Ladurner,et al.  [Prevention of stroke]. , 1999, Wiener klinische Wochenschrift.

[32]  J. Hubacek,et al.  (TTA)n repeat polymorphism in the HMG-CoA reductase gene and cholesterolaemia. , 1999, VASA. Zeitschrift fur Gefasskrankheiten.

[33]  N. Day,et al.  EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. , 1999, British journal of cancer.

[34]  E. Leitersdorf,et al.  HgiAI polymorphism near the HMGCR promoter. , 1990, Nucleic acids research.

[35]  E. Leitersdorf,et al.  ScrFI polymorphism in the 2nd intron of the HMGCR gene. , 1990, Nucleic acids research.

[36]  H. Hobbs,et al.  A high frequency of length polymorphisms in repeated sequences adjacent to Alu sequences. , 1990, American journal of human genetics.